Most active investors · All time

Ranked by rounds participated in, from announcements across all periods. Lead counts include only confirmed lead roles.

Browse by month

151

Future Food FundLatest Oct 14

OlsAro · €5M Seed Mycoverse · €2.4M Pre-Seed

2rounds

0led

Agritech 2

Pre-seed 1, Seed 1

Oct 14, 2026

Details

New companies 2 · Follow-on 0

Stages: Pre-seed 1, Seed 1

OlsAro €5M Seed Mycoverse €2.4M Pre-Seed

152

Nordic Foodtech VCLatest Oct 14

OlsAro · €5M Seed AquaNab · Undisclosed Undisclosed

2rounds

1led

Agritech 1Biotech 1

Seed 1, Undisclosed 1

Oct 14, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 1, Undisclosed 1

OlsAro €5M Seed AquaNab Undisclosed Undisclosed

153

Amgen VenturesLatest Oct 13

Soufflé Therapeutics · $135M Series B BigHat Biosciences · $75M Series C

2rounds

0led

Biotech 2

Series B 1, Series C+ 1

Oct 13, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 1, Series C+ 1

Soufflé Therapeutics $135M Series B BigHat Biosciences $75M Series C

154

Balyasny Asset ManagementLatest Oct 13

Soufflé Therapeutics · $135M Series B TRex Bio · $50M Undisclosed

2rounds

0led

Biotech 2

Series B 1, Undisclosed 1

Oct 13, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 1, Undisclosed 1

Soufflé Therapeutics $135M Series B TRex Bio $50M Undisclosed

155

Bessemer Venture PartnersLatest Oct 13

Soufflé Therapeutics · $135M Series B Converge Bio · $25M Series A

2rounds

0led

AI 1Biotech 1

Series A 1, Series B 1

Oct 13, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

Soufflé Therapeutics $135M Series B Converge Bio $25M Series A

156

Kerna VenturesLatest Oct 13

Undecimal Bio · $18M Seed Aptadir Therapeutics · €40M Seed

2rounds

0led

Biotech 2

Seed 2

Oct 13, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 2

Undecimal Bio $18M Seed Aptadir Therapeutics €40M Seed

157

Safar PartnersLatest Oct 13

Soufflé Therapeutics · $135M Series B GelMEDIX · $13M Seed

2rounds

0led

Biotech 2

Seed 1, Series B 1

Oct 13, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 1, Series B 1

Soufflé Therapeutics $135M Series B GelMEDIX $13M Seed

158

TCG CrossoverLatest Oct 13

Soufflé Therapeutics · $135M Series B Accro Bioscience · $50M Series C

2rounds

0led

Biotech 2

Series B 1, Series C+ 1

Oct 13, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 1, Series C+ 1

Soufflé Therapeutics $135M Series B Accro Bioscience $50M Series C

159

HV CapitalLatest Oct 7

Rivercell · $25M Seed Flinn · $20M Series A

2rounds

1led

Biotech 1Healthtech 1

Seed 1, Series A 1

Oct 7, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 1, Series A 1

Rivercell $25M Seed Flinn $20M Series A

160

ITOCHU CorporationLatest Oct 7

MOLCURE · Undisclosed Strategic investment agreement United Immunity · ¥2.2B Private financing

2rounds

0led

Biotech 2

Undisclosed 2

Oct 7, 2026

Details

New companies 2 · Follow-on 0

Stages: Undisclosed 2

MOLCURE Undisclosed Strategic investment agreement United Immunity ¥2.2B Private financing

161

Asterion VenturesLatest Oct 6

Edonia · €15M Series A financing package including non-dilutive and bank funding Edonia · €2M Pre-seed

2rounds

1led

Foodtech 2

Pre-seed 1, Series A 1

Oct 6, 2026

Details

New companies 1 · Follow-on 1

Stages: Pre-seed 1, Series A 1

Edonia €15M Series A financing package including non-dilutive and bank funding Edonia €2M Pre-seed

162

BlueYard CapitalLatest Oct 6

Sensible Biotechnologies · $47M Series A Transcripta Bio · $24M Series A

2rounds

0led

Biotech 2

Series A 2

Oct 6, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 2

Sensible Biotechnologies $47M Series A Transcripta Bio $24M Series A

163

OTB VenturesLatest Oct 6

Sensible Biotechnologies · $47M Series A Ingenix · €13M Seed+

2rounds

0led

Biotech 2

Seed 1, Series A 1

Oct 6, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 1, Series A 1

Sensible Biotechnologies $47M Series A Ingenix €13M Seed+

164

Shionogi & CoLatest Oct 5

Celaid Therapeutics · ¥400M Series B second close Dioseve · $7M Series A+

2rounds

0led

Biotech 2

Series A 1, Series B 1

Oct 5, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

Celaid Therapeutics ¥400M Series B second close Dioseve $7M Series A+

165

Innovestor Life ScienceLatest Sep 30

AnaCardio · €62.5M Series B Breye Therapeutics · €67.5M Series A

2rounds

0led

Biotech 2

Series A 1, Series B 1

Sep 30, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

AnaCardio €62.5M Series B Breye Therapeutics €67.5M Series A

166

Ljungström family officeLatest Sep 30

AnaCardio · €62.5M Series B Breye Therapeutics · €67.5M Series A

2rounds

1led

Biotech 2

Series A 1, Series B 1

Sep 30, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series B 1

AnaCardio €62.5M Series B Breye Therapeutics €67.5M Series A

167

Voima VenturesLatest Sep 30

Aventix · €1.2M Pre-seed Avenue Biosciences · $5.7M Seed+

2rounds

1led

Biotech 2

Pre-seed 1, Seed 1

Sep 30, 2026

Details

New companies 2 · Follow-on 0

Stages: Pre-seed 1, Seed 1

Aventix €1.2M Pre-seed Avenue Biosciences $5.7M Seed+

168

CE-VenturesLatest Sep 29

Aptadir Therapeutics · €40M Seed Think Bioscience · $55M Series A

2rounds

0led

Biotech 2

Seed 1, Series A 1

Sep 29, 2026

Details

New companies 2 · Follow-on 0

Stages: Seed 1, Series A 1

Aptadir Therapeutics €40M Seed Think Bioscience $55M Series A

169

Cockrell InterestsLatest Sep 29

ai3Bio · $48M Series A Stellular Bio · Undisclosed Series A

2rounds

0led

Biotech 2

Series A 2

Sep 29, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 2

ai3Bio $48M Series A Stellular Bio Undisclosed Series A

170

Ziff Capital PartnersLatest Sep 29

ai3Bio · $48M Series A Stellular Bio · Undisclosed Series A

2rounds

1led

Biotech 2

Series A 2

Sep 29, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 2

ai3Bio $48M Series A Stellular Bio Undisclosed Series A

171

Andreessen Horowitz (a16z)Latest Sep 24

BigHat Biosciences · $75M Series C Third Arc Bio · $52M Series A+

2rounds

0led

Biotech 2

Series A 1, Series C+ 1

Sep 24, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series C+ 1

BigHat Biosciences $75M Series C Third Arc Bio $52M Series A+

172

DFJ GrowthLatest Sep 24

BigHat Biosciences · $75M Series C Cellares · $257M Series D

2rounds

1led

Biotech 2

Series C+ 2

Sep 24, 2026

Details

New companies 2 · Follow-on 0

Stages: Series C+ 2

BigHat Biosciences $75M Series C Cellares $257M Series D

173

Jetstream Venture FundLatest Sep 24

Rejuvenation Technologies · Undisclosed Investment Wonderlab Bio · Undisclosed Strategic

2rounds

—led

Biotech 2

Undisclosed 2

Sep 24, 2026

Details

New companies 2 · Follow-on 0

Stages: Undisclosed 2

Rejuvenation Technologies Undisclosed Investment Wonderlab Bio Undisclosed Strategic

174

LG Technology VenturesLatest Sep 24

BigHat Biosciences · $75M Series C RegCell, Inc. · $44M Series A

2rounds

0led

Biotech 2

Series A 1, Series C+ 1

Sep 24, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series C+ 1

BigHat Biosciences $75M Series C RegCell, Inc. $44M Series A

175

Sigmas GroupLatest Sep 24

BigHat Biosciences · $75M Series C Centivax · $37M Undisclosed

2rounds

0led

Biotech 2

Series C+ 1, Undisclosed 1

Sep 24, 2026

Details

New companies 2 · Follow-on 0

Stages: Series C+ 1, Undisclosed 1

BigHat Biosciences $75M Series C Centivax $37M Undisclosed

176

Digitalis VenturesLatest Sep 23

Enveda · $311M Series E EpiBiologics · $107M Series B

2rounds

0led

Biotech 2

Series B 1, Series C+ 1

Sep 23, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 1, Series C+ 1

Enveda $311M Series E EpiBiologics $107M Series B

177

Durable Capital PartnersLatest Sep 23

Enveda · $311M Series E VieCure · $43M Undisclosed

2rounds

0led

Biotech 1Healthtech 1

Series C+ 1, Undisclosed 1

Sep 23, 2026

Details

New companies 2 · Follow-on 0

Stages: Series C+ 1, Undisclosed 1

Enveda $311M Series E VieCure $43M Undisclosed

178

National Cancer InstituteLatest Sep 23

Tempo Therapeutics · ≤$2.3M NCI SBIR grant Molecular Targeting Technologies, Inc. · $3.2M National Cancer Institute R01 grant

2rounds

0led

Biotech 2

Undisclosed 2

Sep 23, 2026

Details

New companies 2 · Follow-on 0

Stages: Undisclosed 2

Tempo Therapeutics ≤$2.3M NCI SBIR grant Molecular Targeting Technologies, Inc. $3.2M National Cancer Institute R01 grant

179

Navigare VenturesLatest Sep 23

EnginZyme · SEK 75M Equity round Pixelgen Technologies · $15.5M Series B

2rounds

0led

Biotech 2

Series B 1, Undisclosed 1

Sep 23, 2026

Details

New companies 2 · Follow-on 0

Stages: Series B 1, Undisclosed 1

EnginZyme SEK 75M Equity round Pixelgen Technologies $15.5M Series B

180

SingularLatest Sep 23

Basecamp Research · $140M Series C Apoha · Undisclosed Series A

2rounds

1led

Biotech 1Industrial tech 1

Series A 1, Series C+ 1

Sep 23, 2026

Details

New companies 2 · Follow-on 0

Stages: Series A 1, Series C+ 1

Basecamp Research $140M Series C Apoha Undisclosed Series A

“—” in Led means every role for that investor in this period is undisclosed; it does not mean zero leads. New companies counts the first participation in a company in our records; follow-on counts later participation.